论文部分内容阅读
目的 探讨甲磺酸伊马替尼治疗慢性粒细胞白血病患者的疗效及安全性.方法 将50例慢性粒细胞白血病患者分为慢性期组31例及进展期组19例,慢性期组患者给予甲磺酸伊马替尼400 mg·d-1,进展期组患者给予甲磺酸伊马替尼600 mg·d-1.观察48个月.比较两组患者的临床疗效、耐药率、不良反应发生率以及生存率.结果 治疗后慢性期组患者完全血液学缓解率、完全细胞遗传学缓解率及完全分子学缓解率均显著高于进展期组(P<0.01).慢性期组耐药率及不良反应发生率均显著低于进展期组(P<0.01),生存率显著高于进展期组(P<0.01).结论 甲磺酸伊马替尼治疗慢性期慢性粒细胞白血病患者疗效显著优于进展期患者,耐药率低,安全性好,患者生存率高.“,”Objective To explore the efficacy and safety of imatinib mesylate in the treatment of chronic myelogenous leukemia (CML) in chronic and progressive stage. Methods Fifty CML patients were assigned to chronic (n=31) and progressive stage group (n=19),chronic patients treated with imatinib mesylate 400 mg/day,and progressive ones 600 mg/day. They were observed for 48 months. Group efficacies,resistance rates,incidences of adverse reactions and survival rates were compared. Results After treatment complete hematological response (CHR),complete cytogenetic response (CCyR) and complete molecular response (CMoR) rate were significantly higher in chronic than in progressive stage (P<0.01). Resistance rates and incidences of adverse reactions were significantly lower (P<0.01) and survival rate was higher (P<0.01) in chronic than in progressive stage. Conclusion Imatinib mesylate is more effective in CML patients in chronic than in progressive stage and has lower resistance and higher safety and survival rate of patients.